Literature DB >> 6845257

Intrapleural Corynebacterium parvum for malignant pleural effusions.

R Felletti, C Ravazzoni.   

Abstract

A pilot study of topical (intrapleural) treatment with Corynebacterium parvum was carried out in 10 patients with malignant pleural effusions complicating primary or secondary neoplasms and necessitating frequent thoracocentesis for symptomatic relief. The method was aspiration of all intrapleural fluid except a small portion left for dilution, and then injection of 7 mg of a preparation of Corynebacterium parvum suspended in 20 ml of normal saline solution. The treatment was repeated in each case as clinical conditions called for further thoracocentesis. In eight of these 10 patients the treatment resulted in prompt reduction of the rate of accumulation of pleural fluid and a striking change of cell sediment composition, with appreciable reduction in or complete disappearance of malignant cells and a rise in lymphocyte and neutrophil polymorph counts. The best responders were patients with primary pleural mesothelioma. Clinical improvement was evident in all responders.

Entities:  

Mesh:

Year:  1983        PMID: 6845257      PMCID: PMC459478          DOI: 10.1136/thx.38.1.22

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

1.  EXPERIENCES WITH RADIOACTIVE COLLOIDAL GOLD IN THE TREATMENT OF PLEURAL EFFUSION CAUSED BY METASTATIC CANCER OF THE BREAST.

Authors:  T W BOTSFORD
Journal:  N Engl J Med       Date:  1964-03-12       Impact factor: 91.245

2.  [Corynebacterium parvum in advanced cancers. 1st evaluation of the therapeutic activity of this immunostimulin].

Authors:  L Israël; B Halpern
Journal:  Nouv Presse Med       Date:  1972-01-01

3.  Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis.

Authors:  G R Jones
Journal:  Thorax       Date:  1969-01       Impact factor: 9.139

4.  Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: effects on cytotoxicity of tumor-associated macrophages and NK cells.

Authors:  A Mantovani; C Sessa; G Peri; P Allavena; M Introna; N Polentarutti; C Mangioni
Journal:  Int J Cancer       Date:  1981       Impact factor: 7.396

5.  Intracavitary doxorubicin in malignant effusions.

Authors:  S D Desai; A Figueredo
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

6.  Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.

Authors:  H E Webb; S W Oaten; C P Pike
Journal:  Br Med J       Date:  1978-02-11

7.  [Pleural effusion. Local treatment by Corynebacterium parvum].

Authors:  B Serrou; D Cupissol
Journal:  Nouv Presse Med       Date:  1980-06-07

8.  Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days.

Authors:  N Thatcher; B Lamb; R Swindell; D Crowther
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

9.  Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage.

Authors:  G Stiksa; R Korsgaard; B G Simonsson
Journal:  Scand J Respir Dis       Date:  1979-08

10.  Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions.

Authors:  J W Millar; A M Hunter; N W Horne
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

View more
  6 in total

1.  Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax).

Authors:  C M Laroche; M Britton
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

2.  Corynebacterium parvum for malignant pleural effusions.

Authors:  V Foresti
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

3.  Management of recurrent malignant pleural effusion with chemical pleurodesis.

Authors:  Dalokay Kilic; Hadi Akay; Sevket Kavukçu; Hakan Kutlay; Ayten Kayi Cangir; Serkan Enön; Cem Kadilar
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

4.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 5.  Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.

Authors:  Michal Mierzejewski; Piotr Korczynski; Rafal Krenke; Julius P Janssen
Journal:  Respir Res       Date:  2019-11-07

6.  A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.

Authors:  Anna C Bibby; Natalie Zahan-Evans; Emma Keenan; Charles Comins; John E Harvey; Helen Day; Najib M Rahman; Janet E Fallon; Rachael Gooberman-Hill; Nick A Maskell
Journal:  Pilot Feasibility Stud       Date:  2022-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.